AU
UK
CA
US
IND
NZ
Last update at 2026-06-08T20:27:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls
Mon 02 Mar 26, 02:53 PMGSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
Mon 11 Aug 25, 08:19 AM10 Stocks That Pay $100 or More in Dividends
Mon 23 Jun 25, 09:30 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 34729.00M | 24311.00M | 7497.00M | 17682.00M | 11885.00M |
| Minority interest | -35.00000M | -45.00000M | 36.00M | 29.00M | 36.00M |
| Net income | 31372.00M | 21979.00M | 7020.00M | 16273.00M | 11153.00M |
| Selling general administrative | 14305.00M | 12253.00M | 11615.00M | 14350.00M | 14455.00M |
| Selling and marketing expenses | - | - | 197.00M | - | - |
| Gross profit | 65986.00M | 50467.00M | 33216.00M | 41531.00M | 42399.00M |
| Reconciled depreciation | 3609.00M | 3700.00M | 4777.00M | 6010.00M | 6384.00M |
| Ebit | 40030.00M | 24833.00M | 10630.00M | 15137.00M | 16519.00M |
| Ebitda | 43639.00M | 28533.00M | 14066.00M | 19747.00M | 21412.00M |
| Depreciation and amortization | 3609.00M | 3700.00M | 3436.00M | 4610.00M | 4893.00M |
| Non operating income net other | -217.00000M | 4878.00M | -663.00000M | 4508.00M | -2116.00000M |
| Operating income | 40030.00M | 24833.00M | 10630.00M | 15137.00M | 15045.00M |
| Other operating expenses | 63058.00M | 61053.00M | 33148.00M | 37829.00M | 38602.00M |
| Interest expense | 1238.00M | 1291.00M | 1449.00M | 1574.00M | 1316.00M |
| Tax provision | 3328.00M | 1852.00M | 477.00M | 1384.00M | 706.00M |
| Interest income | 1824.00M | 560.00M | 538.00M | 226.00M | 333.00M |
| Net interest income | -987.00000M | -1255.00000M | -1376.00000M | -1348.00000M | -983.00000M |
| Extraordinary items | 6.00M | -434.00000M | 2631.00M | 326.00M | 806.00M |
| Non recurring | 2328.00M | 802.00M | 600.00M | 747.00M | 1044.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 3328.00M | 1852.00M | 477.00M | 1384.00M | 706.00M |
| Total revenue | 100330.00M | 81288.00M | 41908.00M | 51750.00M | 53647.00M |
| Total operating expenses | 28714.00M | 30232.00M | 24456.00M | 27610.00M | 27354.00M |
| Cost of revenue | 34344.00M | 30821.00M | 8692.00M | 10219.00M | 11248.00M |
| Total other income expense net | -5301.00000M | -522.00000M | -3133.00000M | 2545.00M | -2178.00000M |
| Discontinued operations | 6.00M | -434.00000M | 2631.00M | 4.00M | 10.00M |
| Net income from continuing ops | 31401.00M | 22459.00M | 7021.00M | 16298.00M | 11179.00M |
| Net income applicable to common shares | 31372.00M | 21979.00M | 9616.00M | 16273.00M | 11153.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 197206.00M | 181477.00M | 154229.00M | 167488.00M | 159422.00M |
| Intangible assets | 43370.00M | 25146.00M | 28472.00M | 35369.00M | 35211.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 5017.00M | 3820.00M | 3439.00M | 2601.00M | 2461.00M |
| Total liab | 101289.00M | 104014.00M | 90756.00M | 104042.00M | 95664.00M |
| Total stockholder equity | 95661.00M | 77201.00M | 63238.00M | 63143.00M | 63407.00M |
| Deferred long term liab | 1023.00M | 349.00M | 4063.00M | 5578.00M | 3700.00M |
| Other current liab | 29864.00M | 31785.00M | 12639.00M | 11090.00M | 12639.00M |
| Common stock | 476.00M | 473.00M | 470.00M | 468.00M | 467.00M |
| Capital stock | 476.00M | 473.00M | 470.00M | 485.00M | 486.00M |
| Retained earnings | 125656.00M | 103394.00M | 96770.00M | 97670.00M | 89554.00M |
| Other liab | 23348.00M | 22637.00M | 26589.00M | 29736.00M | 30519.00M |
| Good will | 51375.00M | 49208.00M | 49577.00M | 58653.00M | 53411.00M |
| Other assets | 3.00M | 2.00M | -1.00000M | 1.00M | -1.00000M |
| Cash | 416.00M | 1944.00M | 1784.00M | 1305.00M | 1139.00M |
| Cash and equivalents | 416.00M | 1944.00M | 1784.00M | 1121.00M | 1139.00M |
| Total current liabilities | 42138.00M | 42671.00M | 25920.00M | 37304.00M | 31858.00M |
| Current deferred revenue | 2520.00M | 3067.00M | 6269.00M | 5804.00M | 5709.00M |
| Net debt | 34454.00M | 35054.00M | 36490.00M | 50840.00M | 40126.00M |
| Short term debt | 2945.00M | 2241.00M | 2703.00M | 16190.00M | 8836.00M |
| Short long term debt | 2945.00M | 2241.00M | 2703.00M | 16195.00M | 8831.00M |
| Short long term debt total | 34870.00M | 36998.00M | 38274.00M | 52145.00M | 41265.00M |
| Other stockholder equity | -22167.00000M | -20769.00000M | -22314.00000M | -23372.00000M | -15358.00000M |
| Property plant equipment | 19276.00M | 17721.00M | 13900.00M | 13967.00M | 13385.00M |
| Total current assets | 51259.00M | 59693.00M | 35067.00M | 32803.00M | 49926.00M |
| Long term investments | 15069.00M | 21526.00M | 20262.00M | 20147.00M | 2767.00M |
| Net tangible assets | 95661.00M | -104.00000M | 63238.00M | -30896.00000M | -25656.00000M |
| Short term investments | 22316.00M | 29125.00M | 10437.00M | 8525.00M | 17694.00M |
| Net receivables | 14529.00M | 15745.00M | 11194.00M | 12068.00M | 11399.00M |
| Long term debt | 32884.00M | 36195.00M | 37133.00M | 35955.00M | 32909.00M |
| Inventory | 8981.00M | 9059.00M | 8046.00M | 8283.00M | 7508.00M |
| Accounts payable | 6809.00M | 5578.00M | 4309.00M | 4220.00M | 4674.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 256.00M | 262.00M | 235.00M | 303.00M | 351.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8304.00000M | -5897.00000M | -11688.00000M | -11640.00000M | -11275.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 476.00M | 473.00M | 470.00M | 468.00M | 467.00M |
| Preferred stock total equity | - | - | - | 17.00M | 19.00M |
| Retained earnings total equity | 125656.00M | 103394.00M | 96770.00M | 97670.00M | 89554.00M |
| Treasury stock | -113969.00000M | -111361.00000M | -110988.00000M | -110801.00000M | -101610.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 13163.00M | 7679.00M | 4569.00M | 4450.00M | 2799.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 145944.00M | 121782.00M | 119163.00M | 134685.00M | 109497.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 32884.00M | 36195.00M | 37133.00M | 35955.00M | 32909.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 11125.00M | -19517.00000M | -2592.00000M | 9304.00M | 6434.00M |
| Change to liabilities | -803.00000M | 1242.00M | 1856.00M | -3034.00000M | 451.00M |
| Total cashflows from investing activities | -15783.00000M | -22546.00000M | -4271.00000M | -3945.00000M | 4525.00M |
| Net borrowings | -3516.00000M | -1103.00000M | -12755.00000M | 8764.00M | -935.00000M |
| Total cash from financing activities | -14834.00000M | -9816.00000M | -9649.00000M | -8485.00000M | -20441.00000M |
| Change to operating activities | -6500.00000M | 16498.00M | 1357.00M | -1675.00000M | 4.00M |
| Net income | 31401.00M | 22459.00M | 7021.00M | 16302.00M | 11188.00M |
| Change in cash | -1515.00000M | 158.00M | 475.00M | 125.00M | -206.00000M |
| Begin period cash flow | 1983.00M | 1825.00M | 1350.00M | 1225.00M | 1431.00M |
| End period cash flow | 468.00M | 1983.00M | 1825.00M | 1350.00M | 1225.00M |
| Total cash from operating activities | 29267.00M | 32580.00M | 14403.00M | 12588.00M | 15827.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 5064.00M | 5191.00M | 4777.00M | 6010.00M | 6384.00M |
| Other cashflows from investing activities | -12547.00000M | -318.00000M | 573.00M | -11074.00000M | 134.00M |
| Dividends paid | -8983.00000M | -8729.00000M | -8440.00000M | -8043.00000M | 7978.00M |
| Change to inventory | 592.00M | -1125.00000M | -736.00000M | -1050.00000M | -717.00000M |
| Change to account receivables | 261.00M | -3811.00000M | -1249.00000M | -742.00000M | -644.00000M |
| Sale purchase of stock | -2000.00000M | 0.00000M | 425.00M | -8865.00000M | -12198.00000M |
| Other cashflows from financing activities | 3556.00M | 1013.00M | 29120.00M | -735.00000M | -589.00000M |
| Change to netincome | -2742.00000M | -7307.00000M | 2886.00M | 2863.00M | -222.00000M |
| Capital expenditures | 3236.00M | 2711.00M | 2791.00M | 2594.00M | 2196.00M |
| Change receivables | 261.00M | -3811.00000M | -1249.00000M | -742.00000M | -644.00000M |
| Cash flows other operating | 26895.00M | 21402.00M | 6869.00M | -7761.00000M | -612.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -1350.00000M | 218.00M | 483.00M | 158.00M | -89.00000M |
| Change in working capital | -4456.00000M | 12804.00M | -275.00000M | -4031.00000M | -926.00000M |
| Stock based compensation | 872.00M | 1182.00M | 756.00M | 718.00M | 949.00M |
| Other non cash items | 150.00M | -4763.00000M | 3592.00M | -7025.00000M | 437.00M |
| Free cash flow | 26031.00M | 29869.00M | 11612.00M | 9994.00M | 13631.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PFE Pfizer Inc |
-0.42 1.61% | 25.62 | 15.52 | 9.60 | 2.31 | 1.61 | 2.56 | 9.54 |
| LLY Eli Lilly and Company |
17.73 1.57% | 1149.15 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
-0.61 0.26% | 232.16 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-4.16 1.83% | 223.07 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
-4.4 2.37% | 181.55 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
235 East 42nd Street, New York, NY, United States, 10017
| Name | Title | Year Born |
|---|---|---|
| Dr. Albert Bourla D.V.M., DVM, Ph.D. | Chairman & CEO | 1962 |
| Mr. Frank A. D'Amelio | CFO & Exec. VP | 1958 |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical | 1958 |
| Mr. Douglas M. Lankler | Exec. VP & Gen. Counsel | 1966 |
| Mr. John D. Young | Advisor | 1965 |
| Ms. Angela Hwang | Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. | 1966 |
| Mr. David M. Denton | Chief Financial Officer & Exec. VP | 1965 |
| Ms. Jennifer B. Damico | Sr. VP, Controller & Principal Accounting Officer | 1968 |
| Ms. Lidia L. Fonseca | Exec. VP and Chief Digital & Technology Officer | 1969 |
| Mr. Christopher J. Stevo CFA | Sr. VP & Chief Investor Relations Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...